Quick Answer
CNS Pharmaceuticals, Inc. reported R&D Expense of $9.77 million for fiscal year 2025.
CNS Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $9.77M | +5.2% |
| 2024 | $9.29M | -34.1% |
| 2023 | $14.10M | +51.6% |
| 2022 | $9.30M | -5.2% |
| 2021 | $9.81M | +93.7% |
| 2020 | $5.06M | +173.0% |
| 2019 | $1.85M | +8619.3% |
| 2018 | $21.3K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.20M | -48.2% | +88.2% |
| June 30, 2025 | $1.17M | +4.5% | -64.0% |
| March 31, 2025 | $3.24M | +33.4% | -23.6% |
| September 30, 2024 | $4.24M | +24.5% | +280.2% |
| June 30, 2024 | $1.12M | -60.8% | -54.1% |
| March 31, 2024 | $2.43M | -31.9% | -28.7% |
| September 30, 2023 | $3.41M | +54.5% | +19.9% |
| June 30, 2023 | $2.85M | +28.1% | -20.2% |
- CNS Pharmaceuticals, Inc. showed an increase of +5.2% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, CNS Pharmaceuticals, Inc.’s r&d expense has grown by 45848.8% (from $21.3 thousand to $9.77 million).
- The most recent figure is from CNS Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: